Starling Oncology, Inc. (STLNW) stock
STLNWNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLN
$0.03+0.00 (+10.87%)
Close on Oct 30, 2026Market cap $665.51MP/E –Yield –
Starling Oncology shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Starling Oncology's shares outstanding was 103M at Jun 30, 2026. For fiscal 2025 it was 92M, up 23.1% from the year before. The highest annual figure on record is 92M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 92M | +23.1% |
| FY2024 | Dec 31, 2024 | 75M | +1.8% |
| FY2023 | Dec 31, 2023 | 74M | -8.5% |
| FY2022 | Dec 31, 2022 | 81M | +21.7% |
| FY2021 | Dec 31, 2021 | 66M | +12.0% |
| FY2020 | Dec 31, 2020 | 59M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 103M | +10.5% |
| Q1 FY2026 | Mar 31, 2026 | 102M | +32.0% |
| Q4 FY2025 | Dec 31, 2025 | 102M | +34.2% |
| Q3 FY2025 | Sep 30, 2025 | 97M | +29.1% |
| Q2 FY2025 | Jun 30, 2025 | 93M | +24.7% |
| Q1 FY2025 | Mar 31, 2025 | 77M | +3.9% |
| Q4 FY2024 | Dec 31, 2024 | 76M | +2.3% |
| Q3 FY2024 | Sep 30, 2024 | 76M | +2.8% |
| Q2 FY2024 | Jun 30, 2024 | 75M | +0.8% |
| Q1 FY2024 | Mar 31, 2024 | 74M | +1.1% |
| Q4 FY2023 | Dec 31, 2023 | 74M | -23.4% |
| Q3 FY2023 | Sep 30, 2023 | 73M | -7.7% |
| Q2 FY2023 | Jun 30, 2023 | 74M | +1.5% |
| Q1 FY2023 | Mar 31, 2023 | 73M | -3.7% |
| Q4 FY2022 | Dec 31, 2022 | 97M | +37.9% |
| Q3 FY2022 | Sep 30, 2022 | 80M | +20.5% |
| Q2 FY2022 | Jun 30, 2022 | 73M | +10.6% |
| Q1 FY2022 | Mar 31, 2022 | 76M | +21.3% |
| Q4 FY2021 | Dec 31, 2021 | 70M | – |
| Q3 FY2021 | Sep 30, 2021 | 66M | – |
| Q2 FY2021 | Jun 30, 2021 | 66M | – |
| Q1 FY2021 | Mar 31, 2021 | 63M | – |